Document Detail


Monitoring cell therapy using iron oxide MR contrast agents.
MedLine Citation:
PMID:  15579045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Authors:
Jeff W M Bulte; Dara L Kraitchman
Related Documents :
3165305 - Hemin dependent morphological maturation and endogenous porphyrin synthesis by k562 leu...
8554925 - The iron-binding protein ferritin is expressed in cells of the osteoblastic lineage in ...
12772955 - Simazine and metolachlor removal by subsurface flow constructed wetlands.
10938345 - Farnesol-induced cell death and stimulation of 3-hydroxy-3-methylglutaryl-coenzyme a re...
1701305 - Epithelial progenitor cells in the rat trachea.
288065 - Selective hepatic uptake of human beta-hexosaminidase a by a specific glycoprotein reco...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  5     ISSN:  1389-2010     ISO Abbreviation:  Curr Pharm Biotechnol     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-06     Completed Date:  2005-03-08     Revised Date:  2008-05-12    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  567-84     Citation Subset:  IM    
Affiliation:
Department of Radiology and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. jwmbulte@mri.jhu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Count / methods*
Contrast Media*
Drug Delivery Systems / methods*
Ferric Compounds / diagnostic use*
Humans
Image Interpretation, Computer-Assisted / methods
Magnetic Resonance Imaging / methods*
Magnetics*
Molecular Biology / methods
Molecular Probe Techniques*
Molecular Probes
Prognosis
Tissue Therapy / methods*
Grant Support
ID/Acronym/Agency:
K02 HL04193/HL/NHLBI NIH HHS; R01 HL63439/HL/NHLBI NIH HHS; R01 NS045062/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Ferric Compounds; 0/Molecular Probes; 1309-37-1/ferric oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A non-invasive approach to detecting organ rejection by MRI: monitoring the accumulation of immune c...
Next Document:  Progress in the development of melanocortin receptor selective ligands.